AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2015-02-19
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of AR-42 when given together with
decitabine in treating patients with acute myeloid leukemia. AR-42 may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as decitabine, work in different ways to stop the growth of cancer cells,
either by killing the cells or by stopping them from dividing. Giving AR-42 together with
decitabine may kill more cancer cells.